There is, perhaps, no more hotly debated topic in aerodigestive medicine than the role of proton pump inhibitors (PPIs) in the treatment of respiratory symptoms. During the last 5 years, there has been a growing body of adult and pediatric literature highlighting the association of PPI use with the risk of fractures, infections, renal disease, cardiac disease, and even death. Despite this literature, PPIs remain one of the most commonly prescribed medication classes by many pediatric specialists, including otolaryngologists and pulmonologists.1 With the increase in data suggesting that these medications are not as benign as once thought, there is a critical need to treat only patients who truly would benefit from PPIs and to understand the physiologic features behind the patient’s symptoms.
Rosen R, Rahbar R. Proton Pump Inhibitor Use and Outcomes in Children With Respiratory Symptoms. JAMA Otolaryngol Head Neck Surg. 2018;144(7):555–556. doi:10.1001/jamaoto.2018.0466
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: